Close Menu

Amgen

The Government Accountability Office squelched a rumor that has been circulating about the firing of an agency investigator due to errors in a report on for-profit colleges. Additionally, the agency said it has not "identified any problems" with a report on the DTC genomics industry that was led by the same investigator.

The Molecular and Clinical Genetics Panel held a public meeting this week to discuss potential strategies for regulating some DTC genetic tests.

Researchers from Decode Genetics sequenced the genomes of 87 Icelanders and used that data in combination with GWAS to identify a rare variant associated with a high risk of developing sick sinus syndrome, a disease characterized by heart rhythm disorders.

The protocol for the trial, which will study overall survival in Vectibix-treated chemorefractory patients with wild-type KRAS tumors, is currently being reviewed by the FDA.

The researchers have launched a biotech firm, Healthtell, that aims to use immunosignaturing to develop diagnostics for a variety of indications and potentially enable ongoing monitoring of individuals via mailed-in serum samples.

Currently, there is no publicly announced companion diagnostic collaboration between Sanofi and Myriad for iniparib. However, Myriad plans to reach out to Sanofi to gauge the drugmaker's interest in doing a retrospective trial using BRACAnalysis.

CLC Bio, Decode, Biobase, and three other partners will use $2.1 million to develop software to study gene regulation data.

The amount of activity last year on the regulatory, reimbursement, legislative, educational, and intellectual property fronts is a sign that the wheels are slowly shifting toward creating a framework that will someday support and deliver genomically guided medicine, even though plenty of barriers and challenges need to be overcome on the path to that goal.

Movers & Shakers: Jan 7, 2011

Premium

Leroy Hood, Samuel Broder, Mark Velleca, Paul Beresford, Dino DiCamillo

"We plan to experiment with various pricing structures a bit in the coming weeks or months," a 23andMe spokesperson told PGx Reporter recently. "We know that our price point has been a barrier for some people in the past."

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.